Cargando…

Affinity of anti-spike antibodies in SARS-CoV-2 patient plasma and its effect on COVID-19 antibody assays

BACKGROUND: Measuring anti-spike protein antibodies in human plasma or serum is commonly used to determine prior exposure to SARS-CoV-2 infection and to assess the anti-viral protection capacity. According to the mass-action law, a lesser concentration of tightly binding antibody can produce the sam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macdonald, Patrick J., Ruan, Qiaoqiao, Grieshaber, Jessica L., Swift, Kerry M., Taylor, Russell E., Prostko, John C., Tetin, Sergey Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714467/ https://www.ncbi.nlm.nih.gov/pubmed/34971970 http://dx.doi.org/10.1016/j.ebiom.2021.103796

Ejemplares similares

Determining the affinity of anti-SARS-CoV-2 antibody directly in biological samples and the influence of affinity on quantitative antibody assays
por: Macdonald, Patrick J., et al.
Publicado: (2022)

Affinity of anti-spike antibodies to three major SARS-CoV-2 variants in recipients of three major vaccines
por: Macdonald, Patrick J., et al.
Publicado: (2022)

Method for direct measuring antibody affinity in biological sample
por: Ruan, Qiaoqiao, et al.
Publicado: (2023)

A systematic study on the binding affinity of SARS-CoV-2 spike protein to antibodies
por: An, Ke, et al.
Publicado: (2022)

Revealing the SARS-CoV-2 Spike Protein and Specific Antibody Immune Complex Formation Mechanism for Precise Evaluation of Antibody Affinity
por: Plikusiene, Ieva, et al.
Publicado: (2023)

Comparison of the measured values of quantitative SARS-CoV-2 spike antibody assays
por: Müller, Lars, et al.
Publicado: (2022)

Spike Antibody Assays Can Screen For Viral Neutralizing Activity Toward SARS-CoV-2
por: Schuler, Charles, et al.
Publicado: (2022)

Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma
por: Schneider, Matthias M, et al.
Publicado: (2021)

AN ASSAY FOR DETERMINING THE RELATIVE AFFINITY OF TRACE AMOUNTS OF LABELED ANTIBODIES
por: Steiner, Lisa A., et al.
Publicado: (1967)

Statistics of antibody binding to the spike protein explain the dependence of COVID 19 infection risk on antibody concentration and affinity
por: Williams, David E.
Publicado: (2022)

Antibody detection of SARS-CoV spike and nucleocapsid protein
por: Chang, Mau-Sun, et al.
Publicado: (2004)

Antibody-mediated immunity to SARS-CoV-2 spike
por: Errico, John M., et al.
Publicado: (2022)

Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses
por: Yin, Victor, et al.
Publicado: (2021)

SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients
por: Chensue, Stephen W., et al.
Publicado: (2022)

Fever temperatures modulate intraprotein dynamics and enhance the binding affinity between monoclonal antibodies and the spike protein from SARS-CoV-2
por: Kim, Dong Gun, et al.
Publicado: (2022)

Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-spike antibodies
por: Montes-Cobos, Elena, et al.
Publicado: (2023)

Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV
por: Manopo, Ivanus, et al.
Publicado: (2005)

Screening Antibodies Raised against the Spike Glycoprotein of SARS-CoV-2 to Support the Development of Rapid Antigen Assays
por: Cantera, Jason L., et al.
Publicado: (2021)

Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity
por: Phelan, Thomas, et al.
Publicado: (2021)

SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors
por: Terpos, Evangelos, et al.
Publicado: (2021)

Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization
por: McConnell, Scott A., et al.
Publicado: (2023)

Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays
por: Perkmann, Thomas, et al.
Publicado: (2021)

Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective
por: Khatri, Indu, et al.
Publicado: (2020)

Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein
por: Wrobel, Antoni G., et al.
Publicado: (2020)

Neutralizing antibodies targeting SARS-CoV-2 spike protein
por: Xiaojie, Shi, et al.
Publicado: (2021)

SARS-CoV-2 spike therapeutic antibodies in the age of variants
por: Baum, Alina, et al.
Publicado: (2021)

Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
por: Kemp, SA, et al.
Publicado: (2020)

SARS-CoV-2 spike S2-specific neutralizing antibodies
por: Li, Chia-Jung, et al.
Publicado: (2023)

Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands
por: Harms, Mirja, et al.
Publicado: (2020)

Corrigendum: Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective
por: Khatri, Indu, et al.
Publicado: (2021)

Towards an optimal monoclonal antibody with higher binding affinity to the receptor-binding domain of SARS-CoV-2 spike proteins from different variants
por: Neamtu, Andrei, et al.
Publicado: (2023)

Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay
por: Pallett, Scott J.C., et al.
Publicado: (2022)

Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2
por: Liu, Wanbing, et al.
Publicado: (2020)

A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants
por: Vesper, Niklas, et al.
Publicado: (2021)

Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection with the SARS-CoV-2 Omicron Variant
por: Springer, David Niklas, et al.
Publicado: (2022)

A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination
por: Greene, Sarah E., et al.
Publicado: (2023)

Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients
por: Furukawa, Hiroshi, et al.
Publicado: (2022)

Assessment of commercial SARS-CoV-2 antibody assays, Jamaica
por: Butterfield, Tiffany R., et al.
Publicado: (2021)

Antibody Responses to SARS-CoV-2 Infection—Comparative Determination of Seroprevalence in Two High-Throughput Assays versus a Sensitive Spike Protein ELISA
por: Mohanraj, Dinesh, et al.
Publicado: (2021)

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
por: Yang, Lin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ttlsn1bh56s014520qnnl77sbg